New Zealand’s bold experiment with regulating

New Post Public Reply Private Reply Replies (1) Message Board
Hldctravel TexasKeller #2546

New Zealand’s bold experiment with regulating recreational drugs

It’s been nearly a century since the United States began its experiment in prohibiting recreational drugs besides alcohol, caffeine and tobacco — and virtually no one sees the trillion dollar policy as a success. A recent  study [PDF] shows that drug prices have dropped more than 80 percent in the last two decades alone; purity and availability has risen; and overall addiction and death rates haven’t been cut, despite an exponential increase in incarceration since the 1980s.

Even the hardline U.N. drug czar admitted in the annual  World Narcotics Report [PDF] that “the international drug control system is floundering,” citing specifically its inability to match the speed and creativity of Internet-enabled chemists who create and distribute new legal highs like “bath salts” and “fake marijuana” faster than governments can ban them.

But one country is trying a new approach. For the first time in history, New Zealand has created a regulatory body to oversee recreational drugs. Passed by parliament this summer on a vote of 119 to 1, the  legislation has already granted interim approval to over 50 products with names like “Dr. Feelgood,” “4:20,” and “Everest Tibetan Toot.”

The world should closely watch what happens next. If implemented carefully, New Zealand’s new laws offer the first genuinely scientific and public health-oriented approach to dealing with the negative aspects of humanity’s eternal quest for consciousness alteration. Anthropology tells us that getting high is universal — no culture, no matter how remote, lacks chemical experimentation.

After all, few existing U.S. drug laws were based on a medical assessment of the relative risks of alcohol, tobacco, marijuana, heroin, cocaine and others. Instead, they were derived from historical contingencies and, typically, explicit racism.

The first state laws against cocaine, for example, were passed because the drug was believed to make blacks into “fiends” who would rape white women and be impervious to bullets. The first state laws against opium made similar claims about its effects on Chinese railroad workers — and marijuana prohibition followed a scare campaign about its link with Mexicans and blacks and ability to promote violence and interracial liaisons.

By contrast, New Zealand’s new laws specify that products with “low risk” of death, other harms or addiction must be approved — and leaves it up to a scientific committee to define the precise nature and appropriate definition of “low risk.” Drugs that are already illegal will remain so, probably to avoid conflict with international law. The legislation makes no mention of benefits or efficacy, so manufacturers do not have to prove that their drugs are better than placebos.

At least six drugs have already been rejected. However, the law allowed marketers to keep selling products they have submitted for approval, if they’d already been marketed without incident for at least three months. (The rationale was that since bans cannot keep up, it is futile to add more while the approval process is starting.)

Not surprisingly, all new drugs will remain illegal for people under 18. They can only be sold at specific, licensed outlets — not convenience stores or other places frequented by youth — and must carry packaging identifying the ingredients and including health warnings about the known and potential risks. No advertising is permitted, except inside the store itself.

Will this legislation work? It’s certainly an improvement on the current system, which essentially allows new drugs to be marketed worldwide without testing. It also avoids problems with attempts — like pending legislation on which  hearings were held last month in the U.S. Senate — to create blanket bans on all possible analogues of existing psychoactive drugs.

Such prohibitions not only fail to stop chemists from creating newer compounds, but also cause serious problems for healthcare. Many of these substances have potential medical uses — in fact, they are often based on information from pharmaceutical patent applications — but once they are made illegal, drug companies tend to lose interest because of the excess cost and greater risk of rejection when seeking approval. The former top adviser to the British government on drug policy, Dr. David Nutt, has  compared the loss to medicine that results to the delays in scientific advancement caused by the Catholic church’s actions against Galileo and Copernicus.

In the last month alone, we’ve seen several dramatic examples of the harm caused by failure of our current policy. Two college students at a New York dance festival died from taking “Molly” (MDMA, the drug formerly known as ecstasy) of unknown provenance and purity. A drug that causes severe disfigurement — including crocodile-like skin scales, amputations and bone and muscle loss due to improper synthesis of its main ingredient — known as Krokodil, is suspected to have migrated from Russia to Arizona. And a new  report showed that nearly 23,000 emergency room visits in 2011 were linked to “bath salts.”

Of course, regulation won’t make recreational drug use perfectly safe — this is already clear from our experience with tobacco, prescription drugs and alcohol. However, it also won’t add to the harm done by drugs the way incarcerating users and forcing them to rely on the vagaries of the black market does. People will always seek chemical euphoria, enlightenment and escape — so instead of locking them up and ceding the market to organized crime, we need to give them the safest possible choices and spend the money saved on enforcement on treatment and education instead.

Research shows repeatedly that providing safer alternatives — like clean needles, pharmaceutical-quality drugs and safe spaces in which to use them — improves health. By taking both advertising and gangsters out of the mix, New Zealand’s system offers a promising new way. While a drug-free world is clearly impossible, harm reduction already has decades of data behind it.

Creative Edge Nutrition Inc. (FITX) Stock Research Links

FITX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 362

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 39

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 419

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 583

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 407

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Sentry Insurance Company Announces Strategic Acquisition Plans

Updated Category News Views 205

Insights into Sentry Insurance Company's Acquisition Strategy OLDWICK, N.J.--AM Best has announced that the Credit Ratings of Sentry Insurance Company, along with its subsidiaries—collectively known as Sentry—will stay stable after the recent news of their acquisition of The General from American Family Insurance Group. This deal includes Permanent General Assurance...

Continue Reading
Growth Outlook for the Automotive Horn System Market

Updated Category News Views 165

Overview of the Automotive Horn System Market Wilmington, Delaware - A recent market analysis reveals a significant shift in the automotive horn system industry. The report estimates that the market, currently valued at $0.7 billion, is projected to grow to $1.8 billion by the end of the forecast period in 2033, achieving an impressive compound annual growth rate (CAGR)...

Continue Reading
Payoneer Completes Warrant Purchase Offer and Amendments

Updated Category News Views 105

Payoneer Completes Warrant Purchase Offer and Consent Solicitation Payoneer Global Inc. (NASDAQ: PAYO), a financial technology company serving businesses worldwide, has completed its cash offer to buy outstanding Warrants at $0.78 each. The move is designed to simplify Payoneer’s capital structure and give warrant holders a clear cash alternative, while keeping the...

Continue Reading
The Aesthetic Medicine Market's Future: Key Trends to Watch

Updated Category News Views 251

Sales Expectations for the Aesthetic Medicine Market The global aesthetic medicine market was estimated at US$ 83.12 billion recently, with projections indicating a remarkable potential to rise to US$ 233.67 billion by the year 2033. This growth is anticipated at a compound annual growth rate (CAGR) of 12.17% from 2025 through to 2033. Impact of Technological Innovations...

Continue Reading
Bauducco's Florida Expansion Boosts U.S. Manufacturing

Updated Category News Views 74

New Facility Marks a Strategic Shift for Bauducco Imagine three generations crafting baked goods, and then picture this: Bauducco, the Brazilian icon for snacks like wafer cookies and Panettone, boldly stepping onto the U.S. manufacturing stage. They have just swung wide the doors of their largest stateside factory, right in Zephyrhills, Florida. They're not here to...

Continue Reading